Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00678561 |
Study will test effectiveness of an experimental drug applied once or twice daily to two psoriasis plaques.
Requires 1 clinic visit each week for 5 weeks.
Condition | Intervention | Phase |
---|---|---|
Psoriasis |
Drug: CP-690,550 Drug: Placebo Vehicle |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase 2A Randomized, Double-Blind, Vehicle-Controlled, Intra-Individual Comparison Trial Assessing Safety, Toleration, Pharmacokinetics And Pilot Efficacy Of 4 Weeks Treatment With Topical CP-690,550 In Chronic Plaque Psoriasis |
Enrollment: | 81 |
Study Start Date: | October 2008 |
Study Completion Date: | July 2009 |
Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
2% CP-690,550 QD: Experimental |
Drug: CP-690,550
Topical treatment once daily for 28 days
|
0.2% CP-690,550 QD: Experimental |
Drug: CP-690,550
Topical treatment once daily for 28 days
|
0.02% CP-690,550 QD: Experimental |
Drug: CP-690,550
Topical treatment once daily for 28 days
|
2% CP-690,550 BID: Experimental |
Drug: CP-690,550
Topical treatment twice daily for 28 days
|
0.2% CP-690,550 BID: Experimental |
Drug: CP-690,550
Topical treatment twice daily for 28 days
|
0.02% CP-690,550 BID: Experimental |
Drug: CP-690,550
Topical treatment twice daily for 28 days
|
Placebo Vehicle QD: Placebo Comparator |
Drug: Placebo Vehicle
Topical treatment once daily for 28 days
|
Placebo Vehicle BID: Placebo Comparator |
Drug: Placebo Vehicle
Topical treatment twice daily for 28 days
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Pfizer Investigational Site | |
Irvine, California, United States, 92697 | |
Pfizer Investigational Site | |
San Diego, California, United States, 92123 | |
United States, Illinois | |
Pfizer Investigational Site | |
Chicago, Illinois, United States, 60612 | |
United States, Massachusetts | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02111 | |
United States, Michigan | |
Pfizer Investigational Site | |
Ann Arbor, Michigan, United States, 48109-0314 | |
United States, Minnesota | |
Pfizer Investigational Site | |
Fridley, Minnesota, United States, 55432-3134 | |
United States, Missouri | |
Pfizer Investigational Site | |
Saint Louis, Missouri, United States, 63117 | |
United States, North Carolina | |
Pfizer Investigational Site | |
WinstoN Salem, North Carolina, United States, 27157 | |
Pfizer Investigational Site | |
High Point, North Carolina, United States, 27262 | |
United States, Oregon | |
Pfizer Investigational Site | |
Portland, Oregon, United States, 97223 | |
Pfizer Investigational Site | |
Portland, Oregon, United States, 97239 | |
United States, Texas | |
Pfizer Investigational Site | |
Austin, Texas, United States, 78759 | |
United States, Utah | |
Pfizer Investigational Site | |
Salt Lake City, Utah, United States, 84132 | |
Canada | |
Pfizer Investigational Site | |
Quebec, Canada, G1V 4X7 | |
Canada, British Columbia | |
Pfizer Investigational Site | |
Surrey, British Columbia, Canada, V3R 6A7 | |
Canada, Newfoundland and Labrador | |
Pfizer Investigational Site | |
St. John's, Newfoundland and Labrador, Canada, A1C 2H5 | |
Canada, Ontario | |
Pfizer Investigational Site | |
Waterloo, Ontario, Canada, N2J 1C4 | |
Canada, Quebec | |
Pfizer Investigational Site | |
Montreal, Quebec, Canada, H2K 4L5 | |
Pfizer Investigational Site | |
Montreal, Quebec, Canada, H3Z 2S6 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A3921038 |
Study First Received: | May 13, 2008 |
Last Updated: | August 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00678561 History of Changes |
Health Authority: | United States: Food and Drug Administration |
chronic plaque psoriasis, topical treatment |
Skin Diseases Psoriasis Skin Diseases, Papulosquamous |
Skin Diseases Psoriasis Skin Diseases, Papulosquamous |